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Abstract
Background: Data about the use of positive inotropic agents in patients hospitalized with acute decompensated
heart failure (ADHF) is limited.
Methods: The records of 8066 patients with ADHF who were hospitalized at Hamad Medical Corporation, Qatar
from 1991 to 2013 were analyzed to explore demographics and clinical characteristics of the patients according to
inotropic agents use.
Results: Eight hundred fifty eight patients [10.6 %, 95 % CI (10 to 11.3 %)] received intravenous inotropic support.
Patients receiving inotropes were more likely to be female and have preserved ejection fraction when compared to
those not receiving inotropic agents. Comorbidities associated with higher likelihood of receiving inotropic
treatment included acute myocardial infarction, chronic renal impairment, dyslipidemia, hypertension, obesity and
hyperglycemia. Patient on inotropes were more likely to undergone percutaneous coronary intervention (PCI),
intra-aortic balloon pump support and intubation. There were no differences in the mean plasma BNP and CK-MB
levels between the 2 groups. Heart failure patients receiving inotropes also were more likely to have complications
including ventricular tachycardia (2.0 % vs. 0.9 %, p = 0.003), prolonged hospital stay (8.0 vs. 5.0 days, p = 0.001), cardiac
arrest (14.6 % vs. 3.2 %, p = 0.001) and in-hospital mortality (30.8 % vs. 9.1 %, p = 0.001). Over the study period there was
an increase use of inotropic agents and decreased mortality rates.
Conclusion: Inotropic use increased over the period whereas; female gender and conventional cardiac risk factors
were predictors of inotropic agents use in the study.
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Background
Acute heart failure refers to a group of clinical syn-
dromes due to either new-onset heart failure (HF) or
decompensation of chronic HF with symptoms necessi-
tating hospitalization, emergency department visits, or
unscheduled medical attention [1]. Heart failure is a
growing problem resulting in significant morbidity and
mortality and is the most common cause of hospital
admissions in the United States resulting in approxi-
mately 1.1 million hospitalizations annually [2–4].
Common causes of ADHF are coronary artery disease
(CAD) or valvular abnormalities. However, most patients
hospitalized with ADHF have a worsening of preexisting
HF, while up to 20 % of patients have no prior diagnosis
of HF [5].
Patients with ADHF typically present with symptoms
that range in severity from mild volume overload to life-
threatening cardiogenic shock and multi-organ failure
[6]. A general goal in the management includes im-
proved symptoms with hemodynamic stabilization and
increased use of evidence-based therapies to reduce re-
current hospitalization and mortality.
Based on the recent American College of Cardi-
ology/American Heart Association guidelines for the
diagnosis and management of heart failure, patients
who are refractory to diuretics should be managed
with vasodilators as first-line therapy in the absence
of symptomatic hypotension or systolic blood pressure
of less than 90 mmHg. These guidelines also state
that the use of intravenous positive inotropic agents
is a valid option to improve contractility for hospital-
ized patients with heart failure who have evidence of
low ejection fraction, hemodynamic compromise, car-
diogenic shock, or decreased organ perfusion [7]. Of
note, the clinical practice guidelines of the Heart Fail-
ure Society of America [8] and the European Society
of Cardiology [9] have similar recommendations to
that of the American College Cardiology/American
Heart Association. Positive inotropic agents, on the
other hand, have not been shown to reduce length of
hospital stay or mortality when added to standard
care [10]. Additionally, milrinone and dobutamine
have also been shown to be proarrhythmic and cause
more symptomatic hypotension in randomized con-
trolled trials compared to standard care [11]. Several
observational studies including that of the Acute
Decompensated Heart Failure National Registry (AD-
HERE) have also shown increases in mortality with
inotropes when compared with vasodilator therapy
[12]. However, data about trends of inotropic agents
use in ADHF patients over a period of time is
lacking.
We analyzed predictors of overall use of positive
inotropic agents and associated outcomes in patients




This study was conducted in Heart hospital, Doha,
Qatar. Heart Hospital is committed to deliver safe,
high quality care in cardiology and cardiothoracic
surgery for the residents of Qatar, nationals and
expatriates where more than 95 % of cardiac
patients are being treated in the Hospital, making it
an ideal center for observational-based studies. The
state of Qatar is located in the Arabian Peninsula
having approximately 1.7 million population in 2010
most of them being Arab (40 %) followed by Indians
(18 %), Pakistani (18 %), Iranian (10 %) and others
(14 %). In the past decade, cardiovascular diseases
were the leading cause of morbidity and mortality in
the country. Database for patients admitted to the
hospital are maintained electronically and registered
at the cardiology department since January 1991.
Based on these records, patients hospitalized due to
ADHF between 1991 and 2013 were retrospectively
evaluated. Study (#11355) was exempted for review
from Institutional Review Board (IRB), MRC, Hamad
Medical Corporation (HMC) due to its retrospective
nature and study did not contain identifiable private
information and were not collected by investigators
through intervention or interaction with individuals.
The Framingham criteria were used for the
diagnosis of heart failure. The concurrent presence
of either 2 major criteria or 1 major and 2 minor
criterion was required to establish a diagnosis of HF
[13]. Major criteria included paroxysmal nocturnal
dyspnea, neck vein distention, weight loss of 4.5 kg
in 5 days in response to treatment, acute pulmonary
edema, rales, hepatojugular reflux, S3 gallop, central
venous pressure greater than 16 cm water,
circulation time of 25 s, radiographic cardiomegaly,
pulmonary edema, visceral congestion, or
cardiomegaly at autopsy. Minor criteria on the other
hand included nocturnal cough, dyspnea on ordinary
exertion, a decrease in vital capacity by one third the
maximal value recorded, pleural effusion,
tachycardia (heart rate of at least 120 beats per
minute), or bilateral ankle edema that are not
attributed to any other medical condition (e.g.,
cirrhosis, ascites, nephrotic syndrome) [14–17].
Inotropic support is defined as the use of adrenergic
agonists and phosphodiesterase III (PDE) inhibitors.
Doses of inotropic support were defined as the use
of dopamine ≥ 5 μg/kg/min; any dose of epinephrine,
norepinephrine, dobutamine, or milrinone. On the
Aljundi et al. BMC Cardiovascular Disorders  (2016) 16:47 Page 2 of 8
other hand, definition of acute myocardial infarction
(MI) in this study was consistent to the World
Heart Organization criteria. Bedside transthoracic
echocardiography (TTE) was used to measure EF at
admission to coronary intensive care unit. The
presence of diabetes mellitus was based on
documentation in the patient’s previous or current
medical record. The diagnosis of hyperlipidemia was
made by a fasting cholesterol >5.2 mmol⁄L in the
patient’s medical record or any history of treatment
of hyperlipidemia by the patient’s physician. Chronic
renal impairment was defined as creatinine >1.5
upper normal range. Presence of hypertension was
determined by any documentation in the medical
record or treatment by the patient’s physician.
b. Statistical analysis
Descriptive statistics were calculated for all variables
of interest. Patient characteristics were in the form
of mean ± standard deviation (SD) and frequency
with percentages for interval and categorical
variables respectively. The frequencies of categorical
variables were compared using chi-square test while
comparisons were based on independent student
t-test for interval data. To determine the patient
characteristics that were associated with the use of
inotropic agents, variables including age, sex, diabetes
mellitus, hypertension, obesity, dyslipidemia, chronic
renal impairment, ejection fraction, and prior MI were
considered for multivariate logistic regression analysis
using enter method. Adjusted odds ratios (ORs) and
corresponding 95 % confidence intervals (CIs) for each
factor were reported. All tests were 2-tailed and
statistical difference was defined as a p value < =0.05.
All data analyses were carried out using the Statistical
Package for Social Sciences version 19.0 (SPSS, IBM,
Armonk, NY).
Results
The study included 8066 patients, of whom 858 patients
received inotropic agents. Baseline characteristics of the
study population hospitalized with ADHF are displayed
in Tables 1 and 2. The study patients were racially
diverse; fewer patients in the inotropic group were
Asians but more Middle-Eastern Arabs. Patients receiv-
ing inotropes were more likely to be female (38.9 % vs.
33.1 %, p = 0.001), older age (63 vs. 62 years, p = 0.004),
with chronic renal impairment (18.4 % vs. 8.5 %, p =
0.001), on dialysis (1.9 % vs. 0.3 %, p = 0.001), dyslipid-
emic (11.2 % vs. 5.5 %, p = 0.001), hypertensive (69.3 %
vs. 56.9 %, p = 0.001), obese (8.7 % vs. 6.1 %, p = 0.003)
and have diabetes mellitus (66.3 % vs. 57.1 %, p = 0.001)
at the time of admission. The inotropes group was also
more likely to have elevated troponin levels (40.8 % vs.
25.9 %, p = 0.001) and to present with both STsegment
Table 1 Heart Failure Patient Characteristics and Comorbidities
Variable Inotropes No Inotropes p Value
Demographics
Total number, n (%) 858 (10.6) 7208 (89.4)
Age, mean (SD) 63 ± 12 62 ± 12 0.04
Male, n (%) 419 (61.1) 4270 (66.9) 0.001
Middle-Eastern Arabs 674 (78.6) 5472 (73.7)
South Asians 164 (19.1) 1562 (21.7)
Others 20 (2.3) 174 (2.4) 0.001
Patient Characteristics, n (%)
Smoker 141 (16.4) 1043 (14.5) 0.12
Chronic renal impairment 158 (18.4) 612 (8.5) 0.001
Dyslipidemia 96 (11.2) 394 (5.5) 0.001
Hypertension 595 (69.3) 4100 (56.9) 0.001
Diabetes Mellitus 569 (66.3) 4115 (57.1) 0.001
Obesity 75 (8.7) 443 (6.1) 0.003
Menopause 34 (4) 206 (2.9) 0.07
Labs, mean (SD)
Hemoglobin (g/dl) 11.8 ± 5 12 ± 4.9 0.04
Fasting blood sugar,
mmol/L
11 ± 16 12 ± 48 0.81
Serum creatinine,
mmol/L
164 ± 127 131 ± 265 0.01
BNP, (pg/ml) 4195 ± 7450 3090 ± 7650 0.22
Cholesterol, mmol/L 4.3 ± 1.5 4.4 ± 6 0.57
Low density lipoprotein
(LDL), mmol/L
2.46 ± 1.0 2.9 ± 9.8 0.42
High density lipoprotein
(HDL), mmol/L
1.2 ± 1.6 1.6 ± 1.9 0.63
Triglycerides, mmol/L 1.6 ± 1.3 1.6 ± 7.8 0.98
Creatinine kinase
-MB, μ/L
61 ± 192 74 ± 559 0.6
Labs, n (%)
Troponin positive 350 (40.8) 1866 (25.9) 0.001
Cardiac History, n (%)
Admission ejection
fraction≤ 40 %
200 (59.2) 1305 (69.6) 0.001
Rheumatic heart disease 3 (0.3) 43 (0.6) 0.36
ST-elevation myocardial
infarction (STEMI)
74 (8.6) 309 (4.3) 0.001
Non-STEMI (NSTEMI) 53 (6.2) 256 (3.6) 0.001
Unstable angina 64 (7.5) 421 (5.8) 0.06
Cardiomyopathy 125 (14.6) 860 (11.9) 0.03
Pulmonary hypertension 12 (1.4) 80 (1.1) 0.45
Valvular Heart Disease, n (%)
Mitral regurgitation 44 (5.1) 373 (5.2) 0.95
Aortic regurgitation 11 (1.3) 106 (1.5) 0.66
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elevation (8.6 % vs. 4.3 %, p = 0.001) and non-ST-
segment elevation (6.2 % VS. 3.6 %, P = 0.001) myocar-
dial infarction when compared to the non-intropes
group. The inotrope group was also more likely to
undergo percutaneous coronary revascularization (2.0 %
vs. 0.7 %, p = 0.001), and have intra-aortic balloon pump
support (2.6 % vs. 0.4 %, p = 0.001). Interestingly,
patients in the no inotropic support group were more
likely to have lower LV ejection fraction (LVEF ≤ 40 %;
69.6 % vs. 59.2 %, p = 0.001) and more likely to develop
atrial fibrillation (10.1 % vs. 6.2 %, p = 0.001) when com-
pared to those who received inotropic agents. There
were no significant differences between the 2 groups in
regards to the mean plasma BNP levels (4195 ± 7450 vs.
3090 ± 7650) and CKMB levels (61 ± 192 vs. 74 ± 559)
(p = 0.22 and 0.60 respectively).
Outcome
Patients on inotropes group had more cardiovascular
complications including; ventricular tachycardia (2.0 % vs.
0.9 %, p = 0.003), prolonged hospital stay (8.0 vs. 5.0 days,
p = 0.001), cardiac arrest (14.6 % vs. 3.2 %, p = 0.001) and
in-hospital mortality (30.8 % vs. 9.1 %, p = 0.001) (Table 2).
Trends
Inotropes use over the study period significantly increased;
4.6, 9.0, 9.9 14.2 and 17.6 % (p = 0.001) in 1991–95, 1996–
2000, 2001–05, 2006–2010 and after 2010 years respect-
ively (Table 3).
The average mortality rates in patients with ADHF
receiving inotropic agents over 22 years was variable
but decreased recently; 17.7, 27.1, 29.2, 18.8, and 7.3 %
(p = 0.001) in 1991–95, 1996–2000, 2001–05, 2006–
2010 and after 2010 years respectively (Table 4).
Multivariate analysis
Table 5 shows multivariate logistic regression analysis;
the adjusted odds of being treated with any positive ino-
tropic agent were highest in patients who were a history
of hypertension (OR: 1.66, 95 % CI: 1.10 to 2.5) or hav-
ing chronic renal impairment (OR: 1.76, 95 % CI: 1.19 to
2.6) or preserved ejection fraction (OR: 1.92, 95 % CI:
1.27 to 2.9) after adjusting age, gender, hyperglycemia,
obesity, ethnicity and old myocardial infraction.
In terms of evidence-based discharge medications,
more patients in the inotropic support received beta-
blockers at discharge and but ACE inhibitors when com-
pared to patients who did not receive inotropes agents
(Table 6).
Discussion
This 22-year observational study of patients hospitalized
with HF demonstrates 10.6 % need to use inotropic
agents. Patients who received inotropic agents were
older, more likely to be female, local Arabs rather than
Asians with worse cardiovascular risk profile. Inotropic
agents group were more likely to present with acute cor-
onary syndrome when compared to the non-inotropic
agents group. Interestingly, low left ventricular ejection
fraction and BNP were not predictors of its use.
The current observation of inotropic agents use is con-
sistent with that reported from the ADHERE Registry,
which reported ≈ 10 % use of inotropic agents in patients
hospitalized for ADHF in the United States. It is also con-
sistent with other reports in the literature, which varied
from 3 to 12 % [4, 12, 18]. Interestingly we report signifi-
cant increase of inotropic support over the 22 years
period, which may suggest hospitalization of “sicker”
patients, while patients with less severe heart failure are
increasingly managed in the outpatient setting.
Predictors of inotropic agents use
Our study found that the strongest predictors of ino-
trope use were hypertension and chronic renal impair-
ment. Based on data from ADHERE Registry, about
9.6 % of patients hospitalized for ADHF in the United
States received an intravenous inotrope (either milrinone
or dobutamine). Such patients tended to have more







22 (2.6) 28 (0.4) 0.001
Swan-Ganz catheterization 47 (5.5) 82 (1.1) 0.001
Percutaneous coronary
intervention (PCI)
17 (2) 54 (0.7) 0.001
Coronary artery bypass
grafting (CABG)
61 (7.1) 652 (9) 0.06
Intubation 58 (6.8) 76 (1.1) 0.001




4 (0.5) 39 (0.5) 0.78
Left bundle branch
block (LBBB)
29 (3.4) 223 (3.1) 0.65
Supraventricular tachycardia
(SVT)
3 (0.3) 13 (0.2) 0.3
Ventricular tachycardia 17 (2) 65 (0.9) 0.003
Atrial fibrillation 53 (6.2) 726 (10.1) 0.001
Ventricular fibrillation 5 (0.6) 10 (0.1) 0.004
Cardiac arrest 125 (14.6) 232 (3.2) 0.001
In-hospital mortality 193 (30.8) 407 (9.1) 0.001
Complications, mean (SD)
Length of CCU stay 5 ± 7 4 ± 5 0.02
Total days hospitalized 8 ± 34 5 ± 103 0.001
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severe disease, including lower blood pressure, lower
ejection fraction, and higher blood urea nitrogen. The
use of inotropes in the context of normal ejection frac-
tion in our study is also striking because this signifies an
overuse of inotropic medications, a fact that is consist-
ently discouraged. Based on (ADHERE) Registry, out of
more than 150,000 patients, fewer than 3 % had a sys-
tolic BP of <90 mmHg while approximately 50 % had a
preserved systolic function. [19] However, about 14 % of
the patients in ADHERE were treated with an intraven-
ous inotropic agent indicating an overuse of such agents.
Many studies have revealed that the use of inotropic
agents may be associated with increased mortality, espe-
cially in patients with preserved left ventricular function.
Therefore, it is recommended that positive inotropes
only be used in patients who require inotropic support
for low cardiac output.
However, better LVEF observed in inotropic group in
our study may be explained by the susceptibility of these
patients to a sudden drop in ejection fraction, even
though small, compared to patients pre-conditioned to
chronic low ejection fraction. Moreover, our study
patients were not stratified based on other reversible
conditions like sepsis or infection that can lead to an in-
crease in demand and where the use of inotropes is
assumed to improve outcomes.
One of the strongest predictors of inotrope use in our
study was hypertension. Large multicenter registries
revealed that about 70 % of patient hospitalized with
ADHF have fluid overload, normal to elevated blood
pressure with relatively preserved end-organ function,
and no evidence of cardiogenic shock [4, 6, 20]. There-
fore, the use of inotropes, with the main goal of improv-
ing end-organ perfusion, in such patients is not rational.
Of note, for the majority of patients with ADHF with
normal or elevated systemic blood pressure, there are no
data to support a role for inotropic therapy. In this con-
text, it is worth mentioning that 9 % of patients in the
ADHERE Registry received a positive inotrope (dobuta-
mine or milrinone), although only 2 % of patients were
hypotensive. This means that more than 75 % of patients
had no clinical indication for their use signifying an
overuse of such medications.
Based on the European Society of Cardiology guide-
lines for the diagnosis and treatment of acute HF,
patients with ADHF can be classified into one of six
groups based on the clinical presentation [9]. The first 3
categories of patients comprise more than 90 % of
ADHF presentations. These patients normally have rela-
tively preserved left ventricular function with signs and
symptoms of pulmonary edema and hypertension.
Regardless, these findings emphasize the need for well-
designed prospective trials to further establish the
appropriate use of intravenous inotropic therapy in this
population of patients.
The presence of renal dysfunction is relatively com-
mon in heart failure and can reduce the adequacy of di-
uresis. Renal dysfunction in our analysis was a strong
predictor of inotropic use. This observation can be ex-
plained by the fact that when increases in intravenous
boluses or infusions of loop diuretics and addition of
metolazone does not lead to an adequate diuretic re-
sponse, facilitation of diuresis may be enhanced by ino-
tropic therapy by presumably improved renal blood flow
through modest increases in cardiac output [21]. More-
over, at our institution, low-dose dopamine is used in
combination with diuretic therapy, on the supposition
that it can increase renal perfusion and subsequent diur-
esis. In general, patients with clinical evidence for end-
organ hypoperfusion are mostly referred to as having a
low output state. While hypotension is classically consid-
ered a powerful predictor of this hemodynamic profile,
clinical exam findings may inaccurately identify such pa-
tients who may not even present with hypotension [22]
Of note, patients with long standing heart failure, low
output states can be associated with more subtle clinical
findings, such as nausea, abdominal pain, slowed menta-
tion, and fatigue [23]. An extremely important clinical
finding indicating impaired end-organ perfusion is wors-
ening renal function (so- called cardiorenal syndrome), a
finding that usually occurs after initiating intravenous
loop diuretics [24]. More recent data suggest that many
Table 3 Trend of inotropic support in Heart Failure patients
Trend in years 1991–95 1996–2000 2001–05 2006–10 >2010 P value
Inotropic 65(4.6 %) 159(9.0 %) 201(9.9 %) 277(14.2 %) 154(17.6 %) 0.001
Support
Table 4 Trend of mortality in Heart Failure patients
Trend in years 1991–95 1996–2000 2001–05 2006–10 >2010 P value
Mortality 17.7 % 27.1 % 29.2 % 18.8 % 7.3 % 0.001
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patients with cardiorenal syndrome have a relatively pre-
served cardiac output and hypertension making them
amenable to treatment with inotropes [25].
Outcomes
Our analysis provides data that focus on outcomes re-
lated to the mortality of patients treated with inotropic
medications. This consideration is important when com-
paring our results to other published studies evaluating
mortality. Inotropic therapy in certain studies has been
shown to have detrimental effects [5, 10, 26–36], al-
though another meta-analysis was unable to confirm this
view [37]. In ADHERE registry; more than 65,000 pa-
tients from 263 centers across the United States admit-
ted with heart failure were retrospectively analyzed. Data
were utilized to describe the management trends and
outcomes of those patients. Based on the registry, use of
short-term vasodilator therapy was associated with sig-
nificantly lower in hospital mortality when compared to
positive inotropic treatment. A propensity score match-
ing was used to adjust for confounding factors when
comparing patients in both arms. Similarly, the impact
of intravenous inotropic therapy on mortality in patients
hospitalized with ADHF has been validated in the Out-
comes of a Prospective Trial of Intravenous Milrinone for
Exacerbation of Chronic Heart Failure (OPTIMECHF)
study. In this placebo-controlled, randomized, double-
blind clinical trial, the use of intravenous milrinone when
compared to placebo was associated with a higher rate of
early treatment failure, sustained hypotension (10.7 % vs.
3.2 %, p < 0.001), and new onset atrial fibrillation or flutter
(4.6 % vs. 1.5 %, p=0 .004) [10]. There were no improve-
ments in total days hospitalized, symptomatic relief, or
mortality with milrinone compared with placebo. Our
analysis revealed that intravenous inotrope use was associ-
ated with a significant increase in the risk of mortality.
This risk association could not be attributed to the use of
inotropic medications. Therefore, controlling for other
potential risk factors as possible using a propensity score–
adjusted multivariable analysis would be better utilized to
conclude a significant worse prognosis with the independ-
ent use of inotropes compared with the other group. Of
note, in terms of predictors of in-hospital mortality, of the
39 variables examined in ADHERE, the strongest pre-
dictor was a blood urea nitrogen (BUN) of 43 mg/dL or
higher. This was followed by a systolic blood pressure of
less than 115 mmHg and a SCr of 2.75 mg/dL or greater.
In-hospital mortality in the inotrope-treated patients
in our study was close to 31 %. In ADHERE, patients
treated with Inotrops had a high mortality rate (19 %)
than all other non-inodilator-treated patients (14 %) or
patients with preserved ejection fraction not treated with
inotropes (2 %) [12]. Proposed mechanisms of increased
mortality with inotropes in our study include in-hospital
events such as tachyarrhythmias or subclinical myocardial
ischemia and apoptosis through increased sympathetic
stimulation and intramyocardial calcium accumulation
with the use of inotropes. Additionally, many studies have
revealed that the use of inotropic agents may be associated
with increased mortality, especially in patients with pre-
served left ventricular function, which is also consistent
with our observations.
The use of intravenous inotropes increased over the
last years despite the absence of a reasonable indication
with a trend in increasing mortality.
In addition to evaluating the in-hospital mortality rate,
our study also considered other relevant end points,
such as complications of inotropic support, length of
CCU stay, and length of hospital stay. As opposed to the
results of (OPTIME-CHF), our analysis revealed lower
incidence of atrial fibrillation in patients treated with
inotropic support. This fact is interesting as patients in
this group had more cardiovascular risk factors for de-
veloping atrial fibrillation. However, patients on ino-
tropes had more episodes of ventricular tachycardia and
cardiac arrest; associated rhythm was ventricular fibrilla-
tion. We infer that to the use of inotropic agents that
are known to trigger ventricular tachyarrhythmia as such
complications have been confirmed in randomized trials
of inotropic agents versus placebo or vasodilator
Table 5 Multivariate predictors of Inotropes in Patients
Hospitalized with ADHF
Variable Adjusted OR 95 % CI p value
Age 0.99 0.98–1.01 0.33
Male 0.90 0.64–1.27 0.55
Diabetes Mellitus 1.04 0.72–1.50 0.84
Hypertension 1.66 1.10–2.50 0.02
Obesity 1.06 0.66–1.70 0.81
Chronic renal failure 1.76 1.19–2.60 0.005
Ejection fraction >40 1.92 1.27–2.90 0.002
Middle-Eastern Arabs 1.10 0.76–1.58 0.62
Old myocardial infarction 1.19 0.82–1.71 0.36
Table 6 Medication Use at Discharge
Variable Inotropes No Inotropes P Value
ß-blocker 275 (32.1) 1908 (26.5) 0.001
ACE/ARBa 321 (37.4) 4346 (60.3) 0.001
Calcium channel blockers 352 (41) 768 (10.7) 0.001
Digoxin 28 (3.3) 389 (5.4) 0.008
Amiodarone 53 (6.2) 394 (5.5) 0.39
Frusemide 545 (63.5) 6012 (83.4) 0.001
Spiranolactone 35 (4.1) 456 (6.3) 0.009
aACE/ARB: Angiotensin converting enzyme inhibitors/Angiotensin
receptor blockers
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medications used for heart failure [38, 39]. Therefore,
the use of such medications warrant close monitoring
and correction of any cause that can contribute to devel-
opment of arrhythmias.
Length of CCU stay and overall hospital stay was longer
in patients treated with inotropic medications group. This
result is consistent with other registries. For example,
patients who received inotropic agents in ADHERE had
more than double the length of stay (12.9 vs. 5.8 days; P <
0.0001) compared with those who were not treated with
inotropes. Moreover, in a subgroup analysis of ADHERE,
patients with preserved systolic function treated with ino-
tropic agents had longer length of hospital stay (12.9 vs.
5.8 days; P < 0.0001) and more than nine-fold increase in
mortality rate (19 vs. 2 %; P < 0.0001) compared with
patients who did not receive inotropes [40].
One of the important goals in the management of pa-
tients with ADHF is to implement the use of evidence-
based therapies to reduce recurrent hospitalization and
mortality, which include angiotensin converting enzyme
(ACE) inhibitors and beta-blockers [41]. According to
our analysis, more patients in the inotropic support re-
ceived beta-blockers but less ACE inhibitors compared
to no inotropes group (Table 6). This can be explained
by the fact that patients in the inotropic support had
more tachy-arrhythmias that augmented the use of
beta-blockers. . Of note, ACE inhibitors provide rapid
improvement in hemodynamics and renal function that
may facilitate the subsequent initiation of betablockers.
Limitations of the study
Our study had several limitations. First, it is historical
and observational in design with its inherent limitations
including missing data or measurement errors. Addition-
ally, patients were not randomly assigned to the treat-
ment groups and, as a result, both groups differed in
demographics and disease-associated factors related to
the outcomes of interest. Because it is not possible to
identify and adjust for all possible factors, the differences
between patients in both group and the influences of
other nonmeasured factors cannot be totally excluded.
However, we controlled for between-group differences
through multivariate analysis that took into consider-
ation differences in baseline demographics and disease-
associated factors related to the predictors of inotropes
use. We also did not categorize patients based on the
inotropic medication given. The study design cannot
also overcome a bias from the inclusion of a select group
of severe patients who may have been channeled to the
inotropic support group with subsequent worse out-
comes. Additionally, our database did not include clin-
ical data of left ventricular ejection fraction and BNP
throughout 22 years, which are important determinants
of inotrope use and thus may contribute to improved
risk adjustments.
Conclusion
Conventional cardiac risk factors predict the use of ino-
tropic support in heart failure patients. However, there
was some overuse of inotropes in patients with hyper-
tension and preserved ejection fraction. Inotopic agents
use increased over the years.
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